Pharsight

Drugs that contain Oxybutynin

1. Gelnique 3% patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8241662 ALLERGAN Unoccluded topical oxybutynin gel composition and methods for transdermal oxybutynin therapy
Apr, 2020

(4 years ago)

US7029694 ALLERGAN Compositions and methods for transdermal oxybutynin therapy
Apr, 2020

(4 years ago)

US7179483 ALLERGAN Compositions and methods for transdermal oxybutynin therapy
Apr, 2020

(4 years ago)

US7198801 ALLERGAN Formulations for transdermal or transmucosal application
Jun, 2022

(1 year, 11 months ago)

Drug Exclusivity Drug Exclusivity Expiration
New Product(NP) Dec 07, 2014

Market Authorisation Date: 07 December, 2011

Treatment: Treatment of patients with an overactive bladder with symptoms of urinary frequency, urgency, or urge incontinence

Dosage: GEL, METERED;TRANSDERMAL

More Information on Dosage

GELNIQUE 3% family patents

Family Patents

2. Oxytrol patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US5834010 ALLERGAN Triacetin as a penetration enhancer for transdermal delivery of a basic drug
Apr, 2015

(9 years ago)

US5601839 ALLERGAN Triacetin as a penetration enhancer for transdermal delivery of a basic drug
Apr, 2015

(9 years ago)

US7081250 ALLERGAN Compositions and methods for minimizing adverse drug experiences associated with oxybutynin therapy
Apr, 2020

(4 years ago)

US7179483 ALLERGAN Compositions and methods for transdermal oxybutynin therapy
Apr, 2020

(4 years ago)

US7081251 ALLERGAN Compositions and methods for minimizing adverse drug experiences associated with oxybutynin therapy
Apr, 2020

(4 years ago)

US7081249 ALLERGAN Compositions and methods for minimizing adverse drug experiences associated with oxybutynin therapy
Apr, 2020

(4 years ago)

US7081252 ALLERGAN Compositions and methods for minimizing adverse drug experiences associated with oxybutynin therapy
Apr, 2020

(4 years ago)

US6743441 ALLERGAN Compositions and methods for minimizing adverse drug experiences associated with oxybutynin therapy
Apr, 2020

(4 years ago)

Market Authorisation Date: 26 February, 2003

Treatment: Treatment of patients with an overactive bladder with symptoms of urinary frequency, urgency, or urge incontinence

Dosage: FILM, EXTENDED RELEASE;TRANSDERMAL

How can I launch a generic of OXYTROL before it's drug patent expiration?
More Information on Dosage

OXYTROL family patents

Family Patents

Stay ahead of others in designing the generic launch strategy of these 5 blockbuster drugs expiring in next 5 years.

Get the exclusive patent insights now. Don't be the last to know.

3. Oxytrol For Women patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US5834010 ABBVIE Triacetin as a penetration enhancer for transdermal delivery of a basic drug
Apr, 2015

(9 years ago)

US5601839 ABBVIE Triacetin as a penetration enhancer for transdermal delivery of a basic drug
Apr, 2015

(9 years ago)

US7179483 ABBVIE Compositions and methods for transdermal oxybutynin therapy
Apr, 2020

(4 years ago)

US7081250 ABBVIE Compositions and methods for minimizing adverse drug experiences associated with oxybutynin therapy
Apr, 2020

(4 years ago)

US7081251 ABBVIE Compositions and methods for minimizing adverse drug experiences associated with oxybutynin therapy
Apr, 2020

(4 years ago)

US6743441 ABBVIE Compositions and methods for minimizing adverse drug experiences associated with oxybutynin therapy
Apr, 2020

(4 years ago)

US7081252 ABBVIE Compositions and methods for minimizing adverse drug experiences associated with oxybutynin therapy
Apr, 2020

(4 years ago)

US7081249 ABBVIE Compositions and methods for minimizing adverse drug experiences associated with oxybutynin therapy
Apr, 2020

(4 years ago)

Drug Exclusivity Drug Exclusivity Expiration
New Product(NP) Jan 25, 2016

Market Authorisation Date: 25 January, 2013

Treatment: Treatment of patients with an overactive bladder

Dosage: FILM, EXTENDED RELEASE;TRANSDERMAL

More Information on Dosage

OXYTROL FOR WOMEN family patents

Family Patents